Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record.

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Kane, Robert C., Farrell, Ann T., Madabushi, Rajanikanth, Booth, Brian, Chattopadhyay, Somesh, Sridhara, Rajeshwari, Justice, Robert, Pazdur, Richard·2009·The Oncologist

Abstract

Learning Objectives: Evaluate the evidence of improved overall survival with the use of sorafenib for the treatment of unresectable hepatocellular carcinoma. Recognize the potential for drug interactions for sorafenib with concurrent use of drugs that can induce or inhibit CYP3A4. Recognize side effects of sorafenib therapy including elevated blood pressure, diarrhea, fatigue, skin rash/ desquamation, hand–foot skin reaction, alopecia, and nausea, and counsel your patients about side effect management. This article is available for continuing medical education credit at CME.TheOncologist.com.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0185

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 221

Metadata

Authors
Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R.
Venue
The Oncologist
Published
2009-01-01
Volume
14
Issue
1
Pages
95-100
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2151214205
Cited by
221
References
0
FWCI
10.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1634/theoncologist.2008-0185
The paper
Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R. (2009). Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma. The Oncologist. https://doi.org/10.1634/theoncologist.2008-0185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.